Sayed S. Daoud
Associate Professor, Pharmaceutical Sciences Office: 509-368-6572, PBS 415  Lab: 509-368-6715, HSB 315C Spokane


Ph.D. in pharmacology, Medical School, University of Louisville, Louisville, KY
Bachelor of Pharmacy, School of Pharmacy, Cairo University/Egypt


  • Course Director & Instructor – PharDSci 510 (Basics & Clinical Pharmacogenomics), 2 credits, spring semester. Professional Course
  • Course Director & Instructor – PharmSci 520 (Foundations of Molecular Regulation), 3 credits, spring semester. Graduate Course
  • Course Director & Instructor – PharmSci 577 (Introduction to Research), 3 credits, fall semester. Graduate Course


The overall interest of our research program is in translational cancer therapeutics, with a major emphasis on integrating high throughput genomics and proteomics approaches for biomarker discovery and classification for better utility in the molecular pharmacology of cancer.

Current research project

posted December 2012
Dr. Daoud is leading a multidisciplinary team studying the biological basis for racial disparity in liver cancer outcomes in African Americans versus Caucasian Americans.

Using liver cancer tissues from the Kansas University Tissue Bank, and in collaboration with a research team at Harvard Medical School, Daoud and his collaborators have identified 32 proteins – out of 787 quantified – show enormous differences between the two races, meaning a difference in disease progression, disease pathway and/or disease response to treatment. The team has targeted four of those proteins for closer study and will increase the size of its patient base. The proteins under study could represent part of the signaling pathway(s) of the disease etiology.
The team will present this pilot study at the American Association for Cancer Research annual meeting in April 2013.

Methods and compositions for the inhibition of cancer cells. Sayed S. Daoud. Patent No., US6,214,821 B1 (2001)

Selected Publications

Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, Yu Q, LaRose J, Kohn KW, Weinstein JN, Pommier Y. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: A pharmacogenomic study. Cancer Research 63: 2782-2793, 2003

Redkar A, Mixter P, Daoud SS. Implications of p53 in growth arrest and apoptosis on combined treatment of human mammary epithelial cells with topotecan and UCN-01. J. Exp. Ther Oncol 4: 213-222, 2004.

Rehman A, Chahal MS, Tang X, Bruce JE, Pommier Y, Daoud SS. Proteomic identification of heat shock protein 90 (Hsp90) as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Research 7:R765-R774 ( 2005)

Lee K, Wang T, Paszczynski AJ, Daoud SS. Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells. Biochem Biophys Res. Commun 349: 1117-1124, 2006

Wang T, Lee K, Rehman A, Daoud SS. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax. Biochem Biophys Res Commun. 352: 203-212, 2006

Lee K and Daoud SS. Impact of p21 Knockout on Topotecan-Induced Stress Responses in Human Colon Carcinoma Cells: A Proteomic Analysis. The Open Proteomics J. 2: 30-39, 2009

Zekri AR, Bahnassy AA, Alam El-Din HM, Morsy HM, Shaarawy S, Moharram NZ, Daoud SS. Serum Levels of B-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma. Oncol Rep. 26: 825-31, 2011

Zekri AR, Bahnassy AA, Hafez M, Kamel M, Loutfy SA, Sherif GM, Hassan ZK, Daoud SS. Characterization of chronic HCV infection-induced apoptosis. Comp Hepatol 10:4, 2011

Dillon ST, Bhasin MK, Feng X, Koh DW, Daoud SS. Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity. Journal of Translational Medicine 11:239, 2013.

Dasgupta N, Chen YO, Kalyanaraman A, Daoud SS. Comparison of clustering algorithms: An example with proteomic data. Advances & Applications in Statistics 33(1): 63-81, 2013

Daoud SS. Hepatitis C Pharmacogenetics: Possible solutions for an existing problem. J Pharmacogenomics Pharmacoproteomics 4:2, 2013 [Editorial]

Daoud SS. Genome-wide identification of FGFR2 alternative splicing in hepatitis C: Potential roles in malignant transformation. J Pharmacogenomics Pharmacoproteomics 5: e140, 2014 [Editorial]

Yeh MM, Yeung RS, Apisarnthanarax S, Bhattacharya R, Cuevas C, Harris WP, Hon TLK, Padia SA, Park JO, Riggle KM, Daoud SS. Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol 7(11): 1460-83, 2015

Connie Remsberg, Brenda Bray, Susan Wright, Joe Ashmore, William Kabasenche, Shuwen Wang, Phillip Lazarus, Sayed Daoud. Design, implementation, and assessment approaches within a pharmacogenomic course. AJPE 81: 11 – 24, 2017

Matthew M Yeh, Sarag Boukhar, Benjamin Roberts, Nairanjana Dasgupta, Sayed S Daoud. Genomic variants link to hepatitis C racial disparities. Oncotarget 8(35): 59455-59475, 2017

Sayed S. Daoud (Editor). Cancer Proteomics: From Bench to Bedside. Humana Press, 2007

Book chapters
Kyunghee Lee, Tao Wang, Abdur Rehman, Yuhua Wang, Sayed S. Daoud. Integration of genomics and proteomics in dissecting p53 signaling. In: Cancer Proteomics: From Bench to Bedside (Sayed S. Daoud, editor), p39-58. Humana Press, 2007

Dasgupta N, Chen Y, Basu R, Daoud SS. An Application of Unsupervised Learning Methods to Proteomic Data from Colon Cancer. In: Contemporary Topics in Mathematics and Statistics with Applications, Asian Books, Ch 9(1) :170-184, 2013

updated 9/27/2017